Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses

Laura Chiavaroli, Effie Viguiliouk, Stephanie Nishi and 6 more

Nutrients · 2019 · Systematic review · CC BY

doi:10.32920/26521276.v1

Abstract

Background: The Dietary Approaches to Stop Hypertension (DASH) dietary pattern, which emphasizes fruit, vegetables, fat-free/low-fat dairy, whole grains, nuts and legumes, and limits saturated fat, cholesterol, red and processed meats, sweets, added sugars, salt and sugar-sweetened beverages, is widely recommended by international diabetes and heart association guidelines. Objective: To summarize the available evidence for the update of the European Association of the Study of Diabetes (EASD) guidelines, we conducted an umbrella review of existing systematic reviews and meta-analyses using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach of the relation of the DASH dietary pattern with cardiovascular disease and other cardiometabolic outcomes in prospective cohort studies and its effect on blood pressure and other cardiometabolic risk factors in controlled trials in individuals with and without diabetes. Methods: MEDLINE and EMBASE were searched through 3 January 2019. We included systematic reviews and meta-analyses assessing the relation of the DASH dietary pattern with cardiometabolic disease outcomes in prospective cohort studies and the effect on cardiometabolic risk factors in randomized and non-randomized controlled trials. Two independent reviewers extracted relevant data and assessed the risk of bias of individual studies. The primary outcome was incident cardiovascular disease (CVD) in the prospective cohort studies and systolic blood pressure in the controlled trials. Secondary outcomes included incident coronary heart disease, stroke, and diabetes in prospective cohort studies and other established cardiometabolic risk factors in controlled trials. If the search did not identify an existing systematic review and meta-analysis on a pre-specified outcome, then we conducted our own systematic review and meta-analysis. The evidence was summarized as risk ratios (RR) for disease incidence outcomes and mean differences (MDs) for risk factor outcomes with 95% confidence intervals (95% CIs). The certainty of the evidence was assessed using GRADE. Results: We identified three systematic reviews and meta-analyses of 15 unique prospective cohort studies (n = 942,140) and four systematic reviews and meta-analyses of 31 unique controlled trials (n = 4,414) across outcomes. We conducted our own systematic review and meta-analysis of 2 controlled trials (n = 65) for HbA1c. The DASH dietary pattern was associated with decreased incident cardiovascular disease (RR, 0.80 (0.76–0.85)), coronary heart disease (0.79 (0.71–0.88)), stroke (0.81 (0.72–0.92)), and diabetes (0.82 (0.74–0.92)) in prospective cohort studies and decreased systolic (MD, −5.2 mmHg (95% CI, −7.0 to −3.4)) and diastolic (−2.60 mmHg (−3.50 to −1.70)) blood pressure, Total-C (−0.20 mmol/L (−0.31 to −0.10)), LDL-C (−0.10 mmol/L (−0.20 to −0.01)), HbA1c (−0.53% (−0.62, −0.43)), fasting blood insulin (−0.15 μU/mL (−0.22 to −0.08)), and body weight (−1.42 kg (−2.03 to −0.82)) in controlled trials. There was no effect on HDL-C, triglycerides, fasting blood glucose, HOMA-IR, or CRP. The certainty of the evidence was moderate for SBP and low for CVD incidence and ranged from very low to moderate for the secondary outcomes. Conclusions: Current evidence allows for the conclusion that the DASH dietary pattern is associated with decreased incidence of cardiovascular disease and improves blood pressure with evidence of other cardiometabolic advantages in people with and without diabetes. More research is needed to improve the certainty of the estimates.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Cardiovascular disease (CVD) continues to be a leading cause of mortality in people with and without diabetes globally. Clinical practice guidelines recommend dietary strategies as the cornerstone of therapy to prevent and manage cardiovascular disease. The dietary approaches to stop hypertension (DASH) dietary pattern, which emphasizes fruit, vegetables, fat-free/low-fat dairy, whole grains, nuts and legumes, and limits total and saturated fat, cholesterol, red and processed meats, sweets, added sugars, and sugar-sweetened beverages, was originally developed through research sponsored by the US National Institutes of Health (NIH) to treat hypertension without medication and successfully demonstrated a clinically meaningful blood pressure lowering effect.

In addition to reducing blood pressure, the DASH dietary pattern has since been shown to have a decreasing effect on low-density lipoprotein-cholesterol (LDL-C) among other cardiometabolic risk factors in randomized controlled trials and be associated with reductions in diabetes and cardiovascular mortality in prospective cohort studies.

These benefits of the DASH dietary pattern have been recognized by general dietary guidelines from the U.S.-based National Heart, Lung, and Blood Institute (NHLBI) and the United States Department of Agriculture (USDA). International diabetes and cardiovascular clinical practice guidelines have also recommended the DASH dietary pattern for cardiovascular risk reduction. The European Association for the Study of Diabetes (EASD), however, has not reviewed the evidence or made specific recommendations regarding the DASH dietary pattern in its clinical practice guidelines for nutrition therapy. To update current recommendations, the Diabetes and Nutrition Study Group (DNSG) of the EASD commissioned an umbrella review of existing systematic reviews and meta-analyses using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to summarize the available evidence of the relation of the DASH dietary pattern with diabetes and cardiovascular outcomes in prospective cohort studies and its effect on blood pressure and other established cardiometabolic risk factors in randomized and non-randomized controlled trials.

2.1. Design

Public health policy and clinical practice guidelines are established with the use of systematic reviews and meta-analyses of controlled trials and prospective cohort studies, which are regarded as the best levels of evidence. We thus identified the most recent systematic reviews and meta-analyses assessing the relationships of the DASH dietary pattern with incident cardiometabolic diseases in prospective cohort studies and on cardiometabolic risk factors in randomized and non-randomized controlled trials in individuals with and without diabetes. The umbrella review was conducted according to the principals of the Cochrane Handbook for Systematic Reviews of Interventions and the GRADE handbook with reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The study protocol was registered (clinicaltrials.gov identifier, NCT03542370).

2.2. Study selection

The databases Medline and Embase were searched from inception through 3 January 2019 using the search terms “dietary approaches to stop hypertension” or “DASH” and “meta-analysis” (Supplemental Table S1). If the search of systematic reviews and meta-analyses did not identify an existing systematic review and meta-analysis on any of the pre-specified outcomes below, then we conducted our own systematic review and meta-analysis in which studies were eligible if the intervention was a DASH dietary pattern and the outcomes of interest were reported.

2.3. Data extraction

Two independent reviewers extracted relevant data from each included systematic review and meta-analysis and from invidual studies if we had to conduct our own systmatic review and meta-analysis.

2.4. Risk of Bias Assessment

The quality of the individual studies contained in each systematic review and meta-analysis was assessed by the two independent reviewers. Study characteristics were extracted and risk of bias assessments were performed using either the New Castle Ottawa score for the prospective cohort studies or the Cochrane Risk of Bias Tool for the controlled trials.

2.5. Outomes

The primary outcome was incident CVD in the prospective cohort studies and SBP in the controlled trials. Secondary outcomes included incident coronary heart disease (CHD), stroke, and diabetes in the prospective cohort studies and diastolic blood pressure (DBP), blood lipids (Total-cholesterol (Total-C), LDL-C, high-density lipoprotein-cholesterol (HDL-C), and triglycerides), glycemic control (HbA1c, fasting blood glucose, fasting blood insulin, homeostasis model assessment of insulin resistance (HOMA-IR)), adiposity (body weight), and inflammation (C-reactive protein) in the controlled trials.

2.6. Evidence Synthesis

All of the available evidence for each systematic review and meta-analysis identified was summarized, including pooled risk ratios for reports of prospective cohorts and pooled effect estimates of mean differences (MDs) for reports of controlled trials. Where we conducted our own meta-analysis, the generic inverse variance method with fixed or random effects models were used where appropriate.

2.7. Grading of the Evidence

The certainty of the evidence was assessed using the GRADE tool. This tool allows evidence to be graded as high, moderate, low, or very low quality. Randomized controlled trials start as high-quality evidence and observational studies such as prospective cohort studies start as low-quality evidence. Both can then be downgraded or upgraded on the basis of pre-specified criteria. The criteria used to downgrade evidence include study limitations (weight of studies showing risk of bias as assessed by the Cochrane Risk of Bias Tool or the New Castle Ottawa Scale, unless otherwise specified), inconsistency (substantial unexplained inter-study heterogeneity, I2 ≥ 50% and P < 0.10), indirectness (presence of factors that limit the generalizability of the results), imprecision (the 95% confidence intervals (95% CIs) for MDs and risk estimates are wide or cross a minimally important difference), and publication bias (significant evidence of small-study effects). The criteria used to upgrade the quality of evidence are restricted to prospective cohort studies. These criteria include a large magnitude of association (relative risk, (RR) ≤ 0.5 or ≥2), a dose–response gradient, and attenuation by plausible confounding.

3.1. Search Results

Figure 1 illustrates the literature search and selection process. We identified 125 reports from the search, of which 60 were excluded for title and abstract. Of 17 reports that were reviewed in full, seven reports met eligibility criteria and were included. We identified three systematic reviews and meta-analyses of 15 unique prospective cohort studies (n = 942,140) and four systematic reviews and meta-analyses of 31 unique controlled trials (n = 4414) across outcomes.

Cardiovascular Disease Incidence

One systematic review and meta-analysis assessed the relationship between consumption of the DASH dietary pattern and CVD incidence (including incidence and mortality of CVD, CHD, stroke and sudden cardiac death) (Figure 2, Table 1, and Supplemental Table S2). It included 11 prospective cohort comparisons (n = 783,732; 32,927 events) conducted in various countries, including the United States (seven studies), Sweden (two studies), China (one study), and Italy (one study), with follow-up durations ranging from 7.9 to 24 years. The consumption of a DASH dietary pattern was found to significantly reduce CVD (RR = 0.80 (95% CI: 0.76–0.85), which showed no evidence of inter-study heterogeneity (I2 = 30%). No serious risk of bias was identified (Supplemental Tables S3–S4).

Supplemental Table S5 shows the GRADE assessment of the certainty of the evidence for the relationship between the DASH dietary pattern and CVD. The evidence was rated as low for the association of the DASH dietary pattern and CVD incidence. This assessment suggests that the DASH dietary pattern may have a meaningful cardiovascular benefit, but the estimate remains uncertain.

Coronary Heart Disease Incidence

One systematic review and meta-analysis assessed the relationship between consumption of the DASH dietary pattern and CHD incidence (Figure 2, Table 1, and Supplemental Table S6). It included three prospective cohort comparisons (n = 144,337; 7260 events) all of which were conducted in the United States, with follow-up durations ranging from 14.6 to 24 years. The consumption of a DASH dietary pattern was found to significantly reduce CHD incidence (RR = 0.79 (95% CI: 0.71–0.88)), which showed no evidence of inter-study heterogeneity (I2 = 0%). No serious risk of bias was identified (Supplemental Tables S7–S8).

Supplemental Table S5 shows the GRADE assessment of the overall strength of the evidence for the relationship between the DASH dietary pattern and CHD incidence. The evidence was rated as very low for the association of the DASH dietary pattern and CHD incidence, owing to a downgrade for indirectness since the findings are not generalizable given that the three prospective cohort studies were conducted in middle-aged or elderly women. The relationship remains uncertain, with future studies likely to have an important influence on risk estimates.

Stroke Incidence

One systematic review and meta-analysis assessed the relationship between consumption of the DASH dietary pattern and stroke incidence (Figure 2, Table 1 and Supplemental Table S9). It included three prospective cohort comparisons (n = 150,191; 4,413 events) two of which were conducted in the United States and one study in Italy, with follow-up durations ranging from 7.9–24 years. The consumption of a DASH dietary pattern was found to significantly reduce stroke incidence (RR = 0.81 (95% CI: 0.72–0.92)), which showed no evidence of inter-study heterogeneity (I2 = 0%). No serious risk of bias was identified (Supplemental Tables S10–S11).

Supplemental Table S5 shows the GRADE assessment of the certainty of the evidence for the relationship between the DASH dietary pattern and stroke incidence. The evidence was rated as low for the association of the DASH dietary pattern and stroke incidence. This assessment suggests that the DASH dietary pattern may have a meaningful stroke benefit, but the estimate remains uncertain.

Diabetes Incidence

One systematic review and meta-analysis assessed the relationship between consumption of the DASH dietary pattern and diabetes incidence (Figure 2, Table 1, and Supplemental Table S12). It included five prospective cohort studies (n = 158,408; 23,612 events) four of which were conducted in the United States and one study in Europe, with follow-up durations ranging from 5–20 years. The consumption of a DASH dietary pattern was found to significantly reduce diabetes incidence (RR = 0.82 (95% CI: 0.74–0.92)), however showed substantial unexplained inter-study heterogeneity (I2 = 62%). No serious risk of bias was identified (Supplemental Tables S13–S14).

Supplemental Table S5 shows the GRADE assessment of the certainty of the evidence for the relationship between the DASH dietary pattern and diabetes incidence. The evidence was rated as very low for the association of the DASH dietary pattern and diabetes incidence, owing to a downgrade for inconsistency (I² = 62%; P = 0.03), and with <10 studies, no subgroup analyses were performed to attempt to explain heterogeneity. The relationship remains uncertain, with future studies likely to have an important influence on risk estimates.

Blood Pressure

One systematic review and meta-analysis of controlled trials assessed the effect of the DASH dietary pattern on blood pressure outcomes, including SBP and DBP (Figure 3, Table 2, and Supplemental Table S15). A total of nineteen controlled trials were included, involving 1,918 middle-aged participants with and without hypertension. The DASH dietary pattern was found to significantly lower SBP (MD = −5.20 mmHg (95% CI: −7.00 to −3.40 mmHg)) and DBP (MD = −2.60 mmHg (95% CI: −3.50 to −1.70 mmHg)). There was substantial unexplained inter-study heterogeneity across both outcomes (I2 = 76% and 49%, respectively). No serious risk of bias was identified (Supplemental Figures S1–S2).

Supplemental Table S16 shows the GRADE assessments for the certainty of the evidence for the effect of a DASH dietary pattern on blood pressure. The evidence for SBP was rated as moderate, owing to a downgrade for inconsistency (I² = 76%; P < 0.001). The evidence for DBP was rated as low, owing to downgrades for inconsistency (I² = 49%; P = 0.009) and imprecision in the pooled effect estimate. This assessment suggests that the DASH dietary pattern may result in clinically meaningful reductions in blood pressure. The effect of the DASH dietary pattern on DBP, however, remains uncertain, with future randomized controlled trials likely to have an important influence on risk estimates.

Blood Lipids

One systematic review and meta-analysis of controlled trials assessed the effect of the DASH dietary pattern on blood lipid outcomes, including Total-C, LDL-C, HDL-C and triglycerides (Figure 3, Table 2, and Supplemental Tables S17–S19). A total of thirteen controlled trials were included in the analysis of Total-C and LDL-C, involving 1673 middle-aged participants, fifteen trials in the analysis of HDL-C, involving 1749 participants, and 14 trials in the analysis of triglycerides, involving 1654 participants. The DASH dietary pattern was found to lower Total-C (MD = −0.20 mmol/L (95% CI: −0.31 to −0.10 mmol/L)) and LDL-C (MD = −0.10 mmol/L (95% CI: −0.20 to −0.01 mmol/L)) with no significant effects on HDL-C or triglycerides. There was substantial unexplained inter-study heterogeneity for Total-C and HDL-C (I2 = 52% and 76%, respectively), some evidence of inter-study heterogeneity for LDL-C (I2 = 37%) and no evidence of inter-study heterogeneity for triglycerides (I2 = 0%). No serious risk of bias was identified (Supplemental Figures S1–S2).

Supplemental Table S16 shows the GRADE assessments for the certainty of the evidence for the effect of a DASH dietary pattern on blood lipids. The evidence for LDL-C was rated as moderate, owing to a downgrade for imprecision in the pooled effect estimate. The evidence for Total-C, HDL-C, and triglycerides were rated as low, where Total-C and HDL-C were downgraded for inconsistency (I² = 52% and 76%, respectively) and imprecision in the pooled effect estimates and triglycerides was downgraded for imprecision in the pooled effect estimate and for evidence of potential publication bias. This assessment suggests that the DASH dietary pattern may result in reductions in Total-C and LDL-C, established therapeutic lipid targets for cardiovascular risk reduction. However, sources of uncertainty remain. Thus, there is a need for further large, high quality, randomized controlled trials to clarify the lipid-lowering benefits of the DASH dietary pattern.

Glycemic Control

There were no systematic reviews and meta-analyses identified of trials assessing the effect of the DASH dietary pattern on HbA1c. Therefore, we conducted a systematic review and meta-analysis for this outcome. The search (Supplemental Table S20) identified 2 controlled trials (Supplemental Figure S3) which were eligible for inclusion, involving 65 middle-aged participants. The DASH dietary pattern was found to lower HbA1c (MD = −0.53% (95% CI: −0.62 to −0.43%) with significant evidence of inter-study heterogeneity (I2 = 99%) (Figure 3, Table 2, and Supplemental Table S21).

One systematic review and meta-analysis of controlled trials assessed the effect of the DASH dietary pattern on blood glucose, insulin, and HOMA-IR (Figure 3, Table 2, and Supplemental Tables S22–S24). A total of ten controlled trials were included in the analysis of blood glucose, involving 826 middle-aged participants, 11 trials in the analysis of insulin, involving 760 participants, and eight trials in the analysis of HOMA-IR, involving 603 participants. The DASH dietary pattern was found to lower insulin (MD = −0.15 μU/mL (95% CI: −0.22 to −0.08 μU/mL)) with no significant effects on blood glucose or HOMA-IR. There was no evidence of inter-study heterogeneity for insulin (I2 = 0%) or for HOMA-IR (I2 = 16%). There was substantial unexplained inter-study heterogeneity for blood glucose (I2 = 59%) No serious risk of bias was identified (Supplemental Figures S1–S2).

Supplemental Table S16 shows the GRADE assessments for the certainty of the evidence for the effect of a DASH dietary pattern on glycemic control. The evidence for HbA1c was rated as low, owing to downgrades for inconsistency (I² = 99%) and serious indirectness due to <5 studies available for inclusion and lack of generalizability since one study included those with type 2 diabetes and the other women with gestational diabetes. The evidence for blood glucose was also rated as low, owing to downgrades for inconsistency (I2 = 59%) and imprecision in the pooled effect estimate. The evidence for fasting insulin and HOMA-IR were rated as moderate, owing to downgrades for imprecision in the pooled effect estimates. This assessment suggests that the DASH dietary pattern may result in reductions in HbA1c. The effect estimates, however, remain uncertain for most glycemic outcomes, calling for more large, high-quality, randomized trials to clarify the glycemic benefits.

Body Weight

One systematic review and meta-analysis of controlled trials assessed the effect of the DASH dietary pattern on body weight (Figure 3, Table 2, and Supplemental Table S25). A total of 11 controlled trials were included in the analysis of body weight, involving 1211 middle-aged participants. The DASH dietary pattern was found to lower body weight (MD = −1.42 kg (95% CI: −2.03 to −0.82 kg)). There was substantial unexplained inter-study heterogeneity for body weight (I2 = 71%). No serious risk of bias was identified (Supplemental Figures S1–S2).

Supplemental Table S16 shows the GRADE assessments for the certainty of the evidence for the effect of a DASH dietary pattern on body weight. The evidence for body weight was rated as moderate, owing to a downgrade for inconsistency (I² = 71%). This assessment suggests that the DASH dietary pattern may result in meaningful reductions in body weight. The relationship, however, remains uncertain, with future randomized controlled trials likely to have an important influence on risk estimates.

Inflammation

One systematic review and meta-analysis of controlled trials assessed the effect of the DASH dietary pattern on inflammation (Figure 3, Table 2, and Supplemental Table S26). A total of six controlled trials were included in the analysis of the inflammatory marker C-reactive protein (CRP), involving 451 middle-aged participants. The DASH dietary pattern was found not to have an effect on CRP. There was substantial unexplained inter-study heterogeneity for CRP (I2 = 97%). However, subgroup analyses performed by Soltani et al. based on comparator revealed a significant effect compared to unhealthy or usual diets (4 studies) ((MD = −9.62 nmol/L (95% CI: −15.62 to −3.62 nmol/L), I2 = 67.7%), as well as based on follow-up where there was an effect in trials with ≥8 weeks follow-up ((MD = −7.05 nmol/L (95% CI: −12.95 to −1.05 nmol/L), I2 = 92.7%). No serious risk of bias was identified (Supplemental Figures S1–S2).

Supplemental Table S16 shows the GRADE assessments for the certainty of the evidence for the effect of a DASH dietary pattern on CRP. The evidence for CRP was rated as low, owing to downgrades for inconsistency (I2 = 97%) and imprecision in the pooled effect estimate. This assessment suggests uncertainty in whether the DASH dietary pattern has an effect on inflammation. Future randomized controlled trials are likely to have an important influence on risk estimates.

4. Discussion

The present umbrella review of the DASH dietary pattern and cardiometabolic outcomes identified three systematic reviews and meta-analyses of prospective cohort studies involving 15 unique cohort comparisons in 942,140 participants and 32,927 CVD events, 7260 CHD events, 4413 stroke events, 23,612 diabetes events, and four systematic reviews and meta-analyses supplemented by one updated systematic review and meta-analysis of randomized and non-randomized controlled trials involving 33 trial comparisons in 4479 participants on intermediate cardiometabolic risk factors. The DASH dietary pattern was associated with a reduction in the primary outcome of the prospective cohort studies, CVD incidence (20%), as well as reductions in the secondary outcomes: CHD (21%), stroke (19%), and diabetes (18%). These changes were supported by a clinically meaningful reduction in the primary outcome of the controlled trials, blood pressure (−5.2 mmHg for SBP), as well as reductions in the secondary outcomes: DBP (−2.6 mmHg), lipids (−0.1 mmol/L for LDL-C and −0.2 mmol/L for Total-C), body weight (1.42 kg), and HbA1c (−0.53%).

4.1. Findings in the Context of the Literature

The observed cardiovascular benefits may be attributable to a combination of the foods encouraged as part of the DASH dietary pattern. High consumption of fruits and vegetables as part of the DASH dietary pattern have been shown in systematic reviews and meta-analyses of prospective cohort studies, when consumed either together or alone, to be inversely associated with cardiovascular incidence and mortality. Systematic reviews and meta-analyses of prospective cohort studies have also demonstrated that whole grain intake is associated with a 20–21% reduction in CVD incidence and 14% reduction in stroke incidence, dietary pulse intake with a 9% reduction in CVD incidence, and nut intake with a 21% reduction per 28 g/day, while processed and red meats are associated with a 15–18% increase in incidence of CVD mortality comparing highest to lowest levels of intake. A key nutrient richly found in many of the foods emphasized which may contribute a biological effect includes dietary fibre, which has been shown in systematic reviews and meta-analyses of prospective cohort studies to reduce CVD by 9% per 7g/d intake and reduced risks of CHD and stroke incidence of 24% and 22%, respectively, when comparing highest to lowest intake groups, in addition to significant reductions in body weight, Total-C, LDL-C, and SBP in controlled clinical trials. CVD benefit may be the result of the biological effects of other key nutrients richly found in foods emphasized in the DASH dietary pattern, such as magnesium, potassium, and phytochemicals, including flavonoids, which have been demonstrated to have anti-inflammatory and anti-antioxidant activity and result in reductions in angiogenesis. The blood pressure lowering effect of the DASH diet may play a major role, since high blood pressure is ranked as the strongest risk factor attributable to chronic disease. Furthermore, the observed 5.20-mmHg lowering in SBP by the DASH dietary pattern is clinically relevant based on evidence from prospective studies showing that a 2-mmHg reduction in SBP is associated with lower mortality from stroke (10%) and CHD or other vascular causes (7%) in middle-aged men and women. An additional contribution may be via a reduction in established therapeutic lipid targets for cardiovascular risk, such as the observed 0.10mmol/L lowering in LDL-C, which would translate to about a 2% reduction in major cardiovascular events based on the Cholesterol Treatment Trialists' (CTT) Collaboration. The observed overall 1.42 kg reduction in body weight may be considered clinically relevant and may also play a role since obesity is a key risk factor for CVD. Furthermore, a recent prospective cohort not captured in the systematic review and meta-analysis on the DASH dietary pattern and composite CVD outcomes, but which also supports the findings, showed an 11% reduced risk of all-cause mortality when comparing those participants who had the greatest improvement in DASH diet quality score over a 12-year follow-up period compared to those with a relatively stable diet quality. Importantly, they also found a 9% reduced risk among those who maintained a high-quality DASH diet score over the 12-year period compared to those with consistently low diet scores over time. These results highlight the CVD benefit of not only adopting or increasing adherence to a DASH dietary pattern, but also to maintaining a high compliance to it.

The observed reductions in diabetes incidence and improvements in glycemic control again may be attributable to the high consumption of fruit and vegetables as well as the low-fat dairy component of the DASH dietary pattern. Systematic reviews and meta-analyses have shown that fruit and vegetables alone or together and low-fat milk and yogurt are associated with reduced diabetes incidence. Again, dietary fibre coming from many of the foods may play a role since a recent systematic review and meta-analysis of prospective cohort studies found a 16% reduction in incidence of type 2 diabetes when comparing the highest to lowest fibre intakes84. The blood pressure lowering effects of the DASH diet may contribute to this effect since hypertension is associated with type 2 diabetes, where prospective cohort studies have demonstrated that a 1-mmHg increase in SBP is associated with a 1%–4% increase in type 2 diabetes risk. The observed reduction in body weight may also contribute since body weight is strongly associated with diabetes risk. The increase in legumes, nuts, fruit, whole grains and dietary fibre intake, especially from whole grain viscous fibres, as part of a DASH diet may also be the mechanism by which there is a reduction in HbA1c, since these have been demonstrated to improve glycemic control in systematic reviews and meta-analyses of randomized controlled trials and have been associated with reduced diabetes incidence in systematic reviews and meta-analyses of prospective cohort studies.

The DASH diet was originally developed to contain foods which increase magnesium, potassium, and calcium based on established links to lower blood pressure and successfully demonstrated a clinically meaningful blood pressure lowering effect. Interactions between these nutrients can also have blood pressure lowering effects, such as the sodium-to-potassium ratio or the interaction between potassium and calcium and the ability to increase sodium excretion by the kidneys. Potassium and calcium have previously been demonstrated to interact with the renin-angiotensin system by affecting plasma renin activity and potassium can assist with sodium balances and has also been demonstrated to potentially lower blood pressure through endothelium-dependent vascular effects. Additionally, it has been suggested that a reduction in blood pressure may result from an increased intake of nitrate-rich foods, including fruits and vegetables, especially leafy vegetables, via the role of inorganic nitrate in the non-enzymatic generation of nitric oxide. Furthermore, many of the foods encouraged on the DASH diet have demonstrated blood pressure reductions in systematic reviews and meta-analyses of controlled trials in those with and without diabetes, including legumes, fruit, and whole grains, particularly those rich in viscous fibres.

The observed reductions in lipids, including the primary lipid target for therapy, LDL-C, may be attributable to the high consumption of fruit, nuts, legumes, and whole grains (especially from oats and barley), increases in dietary fibre, and reductions in saturated fat intake as part of the DASH dietary pattern. Systematic reviews and meta-analyses of randomized controlled trials have shown that each of these alone or combined as part of cholesterol-lowering dietary patterns such as the Portfolio dietary pattern lowers Total-C and LDL-C.

The effect of the DASH dietary pattern on body weight may result from increased fruit and vegetable consumption, as was found in a systematic review and meta-analysis of randomized controlled trials. Greater dietary fibre intake may contribute to weight loss since high-fibre foods require longer chewing time and promote gastric distention, triggering signals of fullness and slowed digestion, and delayed absorption of nutrients could delay hunger and subsequent energy intake. Increasing dietary pulse intake has also been demonstrated in systematic reviews and meta-analyses of controlled trials to reduce body weight and increase satiety. Reduced sodium intake may also play a role in lowering body weight since high sodium intake is associated with obesity in the general population, possibly because of the associated increase in thirst and appetite.

Although a significant effect on CRP was not observed in the primary pooled analyses, subgroup analyses demonstrated that when the DASH diet was compared to an unhealthy or usual diet as opposed to a healthy diet (e.g. Portfolio diet) or when the follow up duration was ≥8 weeks, the DASH diet resulted in a significantly lower CRP. If this is a true effect, then the reduction in inflammation may also play a key role in the observed reduction in incidence of cardiometabolic diseases. The effect may be mediated by increased dietary fibre intake possibly because of the delay in glucose absorption and alteration to gut microflora which may suppress inflammatory cytokines production, stimulate the production of short-chain fatty acids and lead to lower circulating free fatty acid concentrations and, thus, subsequent inflammation. The effect may also be the result of increased fruit and vegetable intake due to possible anti-inflammatory effects and increased magnesium intake. The high content of vitamin C, calcium and magnesium coming from fruits and vegetables in the DASH dietary pattern may reduce inflammation through reductions in oxidative stress via decreased NADPH oxidase activity and by restoring the activity of anti-oxidative enzymes.

4.2. Strengths and limitations

The strengths of the current umbrella review include that the included systematic reviews and meta-analyses were all conducted recently with the census dates of each ranging from January 2012 to November 27, 2018 and an assessment of the overall certainty of the evidence was performed using the GRADE approach. The limitations include: indirectness for CHD incidence due to the inclusion of cohorts limited to middle-aged and elderly women and for HbA1c due to the inclusion of 2 trials in either type 2 diabetes or gestational diabetes; unexplained inconsistency for diabetes incidence (I² = 62%; P = 0.03) and for 8/12 risk factors; imprecision for 9/12 risk factors; and publication bias for triglycerides. Although we did not downgrade the evidence for indirectness, concern may be raised that many of the included trials and cohorts were conducted in people without diabetes. We did not feel that there was any biological reason to believe that the DASH dietary pattern would behave differently in people with diabetes, as many components of the DASH dietary pattern have been shown individually to lower blood pressure and other established CVD risk factors in systematic reviews and meta-analyses of randomized controlled trials inclusive of people with diabetes without any evidence of a subgroup effect by diabetes status.We also felt that this concern was mitigated by the evidence of similar or greater improvements in all of the measured outcomes (SBP, DBP, LDL-C, Total-C, HDL-C, TG, HbA1c, body weight, CRP) in those trials conducted exclusively in diabetes (that is, the effect estimates for these outcomes in the individual trials were contained within or exceeded the 95% confidence intervals of the overall pooled estimates).

Weighing the strengths and limitations, the certainty of the evidence based on the GRADE approach was rated as very low to low for associations with cardiometabolic disease incidence and low to moderate for effects on cardiometabolic risk factors.

4.3. Implications

Clinical practice guidelines recommend dietary strategies as the cornerstone of the prevention and management of CVD. Our pooled analyses demonstrate that the DASH dietary pattern is associated with a 20% reduced CVD incidence and has blood pressure benefits which may translate to about a 20% reduction in risk of CVD, along with meaningful benefits in other established CVD risk factors in those with and without diabetes. In the systematic review and meta-analysis on the DASH dietary pattern and blood pressure, trials included participants who were hypertensive but not on medication, as well as trials where participants were taking blood pressure medications, all of which found significant blood pressure lowering effects. Thus, the DASH dietary pattern may play a role both as a first line therapy as well as an add-on therapy.

There may be an important opportunity for people with and without diabetes to realize the CVD benefits of a DASH dietary pattern. The DASH dietary pattern emphasizes fruit, vegetables, low-fat dairy, whole grains, nuts and legumes, and limits total and saturated fat. Specifically, the DASH diet includes 4–5 servings of fruits and vegetables per day, 2–3 servings of low fat dairy, 6–8 servings of whole grains and limits meat, poultry and fish to less than six servings per day. It also recommends 4–5 servings per week of nuts, seeds, dry beans, and peas and choosing foods with low saturated fat, high potassium and fibre, and low sodium. Dietary intake patterns in Europe and other Western countries do not currently meet these targets. The European Health Interview Survey (EHIS) (Eurostat 2016) reports that, on average, more than a third of the EU adults do not consume any fruits and vegetables on a daily basis and only 14.1% consume five portions per day; about one third of those aged 35 and older had average intakes of saturated fat ≥15 E%; although a high total consumption of dairy products was reported in the Dutch, Swedish and Danish, and most of Spain and the UK, a somewhat low consumption was reported Greece and in some of Italy (Ragusa and Turin). According to the most recent survey in the United States, only one in 10 adults and youths eat the recommended amount of fruits or vegetables, only 1.9 servings/day of dairy products are consumed on average, only ~38.2% of adults consume nuts on a given day and most exceed the recommendations for added sugars, saturated fats, and sodium. These data suggest that in these populations that there is an opportunity for people with and without diabetes to increase these foods to achieve a DASH dietary pattern and realize the cardiometabolic benefits.

5. Conclusions

In conclusion, this synthesis of systematic reviews and meta-analyses demonstrates that the DASH dietary pattern as a well-accepted blood pressure-lowering diet has associated CVD benefit supported by reductions in blood pressure, HbA1c, LDL-C and other established CVD risk factors in people with and without diabetes. The certainty of the evidence based on the GRADE approach was very low to low for associations with cardiometabolic disease incidence and low to moderate for effects on cardiometabolic risk factors. More research is needed to improve the estimates and confirm that these benefits do translate into reductions in clinical outcomes of clinical practice and public health importance. In this regard, there remains a need for large randomized trials of the effect of the DASH dietary pattern on clinical CVD outcomes in those with and without diabetes. The available evidence does support a potential opportunity for those with and without diabetes to adopt the DASH dietary pattern to improve cardiometabolic health.

References 149

  1. 1.

    International Diabetes Federation. IDF Diabetes Atlas. 2015.

    Not in our library

  2. 2.

    O’Rourke K., VanderZanden A., Shepard D., Leach-Kemon K. Cardiovascular disease worldwide, 1990–2013. JAMA. 2015;314:1905.

    Not in our library10.1001/jama.2015.14994

  3. 3.

    World Health Organization (WHO). Obesity.

    Not in our library

  4. 4.

    Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.

    Not in our library10.1001/jama.289.19.2560

  5. 5.

    American Heart Association Nutrition Committee, Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., Franklin B., Kris-Etherton P., Harris W.S., et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96.

    Not in our library10.1161/circulationaha.106.176158

  6. 6.

    Anderson T.J., Gregoire J., Pearson G.J., Barry A.R., Couture P., Dawes M., Francis G.A., Genest J., Grover S., Gupta M., et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can. J. Cardiol. 2016;32:1263-1282.

    Not in our library10.1016/j.cjca.2016.07.510

  7. 7.

    Evert A.B., Boucher J.L., Cypress M., Dunbar S.A., Franz M.J., Mayer-Davis E.J., Neumiller J.J., Nwankwo R., Verdi C.L., Urbanski P., et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014;37(Suppl. 1):S120-S143.

    Not in our library10.2337/dc14-s120

  8. 8.

    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Dworatzek P.D., Arcudi K., Gougeon R., Husein N., Sievenpiper J.L., Williams S.L. Nutrition therapy. Can. J. Diabetes. 2013;37(Suppl. 1):S45-S55.

    Not in our library10.1016/j.jcjd.2013.01.019

  9. 9.

    Nerenberg K.A., Zarnke K.B., Leung A.A., Dasgupta K., Butalia S., McBrien K., Harris K.C., Nakhla M., Cloutier L., Gelfer M., et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can. J. Cardiol. 2018;34:506-525.

    Not in our library10.1016/j.cjca.2018.02.022

  10. 10.

    Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., Obarzanek E., Conlin P.R., Miller E.R., Simons-Morton D.G., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 2001;344:3-10.

    Not in our library10.1056/nejm200101043440101

  11. 11.

    Siervo M., Lara J., Chowdhury S., Ashor A., Oggioni C., Mathers J.C. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: A systematic review and meta-analysis. Br. J. Nutr. 2015;113:1-15.

    Not in our library10.1017/s0007114514003341

  12. 12.

    Jannasch F., Kroger J., Schulze M.B. Dietary Patterns and Type 2 Diabetes: A Systematic Literature Review and Meta-Analysis of Prospective Studies. J. Nutr. 2017;147:1174-1182.

    Not in our library10.3945/jn.116.242552

  13. 13.

    Schwingshackl L., Hoffmann G. Diet quality as assessed by the Healthy Eating Index, the Alternate Healthy Eating Index, the Dietary Approaches to Stop Hypertension score, and health outcomes: A systematic review and meta-analysis of cohort studies. J. Acad. Nutr. Diet. 2015;115:780-800 e785.

    Not in our library10.1016/j.jand.2014.12.009

  14. 14.

    U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 2015.

    Not in our library

  15. 15.

    Diabetes Canada Clinical Practice Guidelines Expert Committee, Sievenpiper J.L., Chan C.B., Dworatzek P.D., Freeze C., Williams S.L. Nutrition Therapy. Can. J. Diabetes. 2018;42(Suppl. 1):S64-S79.

    Not in our library10.1016/j.jcjd.2017.10.009

  16. 16.

    Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corra U., Cosyns B., Deaton C., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016;37:2315-2381.

    Not in our library10.1093/eurheartj/ehw106

  17. 17.

    Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hubbard V.S., Lee I.M., Lichtenstein A.H., Loria C.M., Millen B.E., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014;63:2960-2984.

    Not in our library10.1016/j.jacc.2013.11.003

  18. 18.

    Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. Cochrane Collaboration.

    Not in our library

  19. 19.

    Guyatt G., Oxman A.D., Akl E.A., Kunz R., Vist G., Brozek J., Norris S., Falck-Ytter Y., Glasziou P., DeBeer H., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 2011;64:383-394.

    Not in our library10.1016/j.jclinepi.2010.04.026

  20. 20.

    Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010;8:336-341.

    Not in our library10.1016/j.ijsu.2010.02.007

  21. 21.

    Wells G.A., Shea B., O’Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014.

    Not in our library

  22. 22.

    Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A., et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Not in our library10.1136/bmj.d5928

  23. 23.

    Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J., Vist G.E., Falck-Ytter Y., Meerpohl J., Norris S., et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 2011;64:401-406.

    Not in our library10.1016/j.jclinepi.2010.07.015

  24. 24.

    Brunetti M., Shemilt I., Pregno S., Vale L., Oxman A.D., Lord J., Sisk J., Ruiz F., Hill S., Guyatt G.H., et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J. Clin. Epidemiol. 2013;66:140-150.

    Not in our library10.1016/j.jclinepi.2012.04.012

  25. 25.

    Guyatt G., Oxman A.D., Sultan S., Brozek J., Glasziou P., Alonso-Coello P., Atkins D., Kunz R., Montori V., Jaeschke R., et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J. Clin. Epidemiol. 2013;66:151-157.

    Not in our library10.1016/j.jclinepi.2012.01.006

  26. 26.

    Guyatt G.H., Oxman A.D., Kunz R., Atkins D., Brozek J., Vist G., Alderson P., Glasziou P., Falck-Ytter Y., Schunemann H.J. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J. Clin. Epidemiol. 2011;64:395-400.

    Not in our library10.1016/j.jclinepi.2010.09.012

  27. 27.

    Guyatt G.H., Oxman A.D., Kunz R., Brozek J., Alonso-Coello P., Rind D., Devereaux P.J., Montori V.M., Freyschuss B., Vist G., et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J. Clin. Epidemiol. 2011;64:1283-1293.

    Not in our library10.1016/j.jclinepi.2011.01.012

  28. 28.

    Guyatt G.H., Oxman A.D., Kunz R., Woodcock J., Brozek J., Helfand M., Alonso-Coello P., Falck-Ytter Y., Jaeschke R., Vist G., et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J. Clin. Epidemiol. 2011;64:1303-1310.

    Not in our library10.1016/j.jclinepi.2011.04.014

  29. 29.

    Guyatt G.H., Oxman A.D., Kunz R., Woodcock J., Brozek J., Helfand M., Alonso-Coello P., Glasziou P., Jaeschke R., Akl E.A., et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J. Clin. Epidemiol. 2011;64:1294-1302.

    Not in our library10.1016/j.jclinepi.2011.03.017

  30. 30.

    Guyatt G.H., Oxman A.D., Montori V., Vist G., Kunz R., Brozek J., Alonso-Coello P., Djulbegovic B., Atkins D., Falck-Ytter Y., et al. GRADE guidelines: 5. Rating the quality of evidence—Publication bias. J. Clin. Epidemiol. 2011;64:1277-1282.

    Not in our library10.1016/j.jclinepi.2011.01.011

  31. 31.

    Guyatt G.H., Oxman A.D., Santesso N., Helfand M., Vist G., Kunz R., Brozek J., Norris S., Meerpohl J., Djulbegovic B., et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J. Clin. Epidemiol. 2013;66:158-172.

    Not in our library10.1016/j.jclinepi.2012.01.012

  32. 32.

    Guyatt G.H., Oxman A.D., Sultan S., Glasziou P., Akl E.A., Alonso-Coello P., Atkins D., Kunz R., Brozek J., Montori V., et al. GRADE guidelines: 9. Rating up the quality of evidence. J. Clin. Epidemiol. 2011;64:1311-1316.

    Not in our library10.1016/j.jclinepi.2011.06.004

  33. 33.

    Guyatt G.H., Oxman A.D., Vist G., Kunz R., Brozek J., Alonso-Coello P., Montori V., Akl E.A., Djulbegovic B., Falck-Ytter Y., et al. GRADE guidelines: 4. Rating the quality of evidence—Study limitations (risk of bias). J. Clin. Epidemiol. 2011;64:407-415.

    Not in our library10.1016/j.jclinepi.2010.07.017

  34. 34.

    Guyatt G.H., Thorlund K., Oxman A.D., Walter S.D., Patrick D., Furukawa T.A., Johnston B.C., Karanicolas P., Akl E.A., Vist G., et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J. Clin. Epidemiol. 2013;66:173-183.

    Not in our library10.1016/j.jclinepi.2012.08.001

  35. 35.

    Agnoli C., Krogh V., Grioni S., Sieri S., Palli D., Masala G., Sacerdote C., Vineis P., Tumino R., Frasca G., et al. A priori-defined dietary patterns are associated with reduced risk of stroke in a large Italian cohort. J. Nutr. 2011;141:1552-1558.

    Not in our library10.3945/jn.111.140061

  36. 36.

    Bertoia M.L., Triche E.W., Michaud D.S., Baylin A., Hogan J.W., Neuhouser M.L., Tinker L.F., Van Horn L., Waring M.E., Li W., et al. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. Am. J. Clin. Nutr. 2014;99:344-351.

    Not in our library10.3945/ajcn.112.056135

  37. 37.

    Fitzgerald K.C., Chiuve S.E., Buring J.E., Ridker P.M., Glynn R.J. Comparison of associations of adherence to a Dietary Approaches to Stop Hypertension (DASH)-style diet with risks of cardiovascular disease and venous thromboembolism. J. Thromb. Haemost. 2012;10:189-198.

    Not in our library10.1111/j.1538-7836.2011.04588.x

  38. 38.

    Folsom A.R., Parker E.D., Harnack L.J. Degree of concordance with DASH diet guidelines and incidence of hypertension and fatal cardiovascular disease. Am. J. Hypertens. 2007;20:225-232.

    Not in our library10.1016/j.amjhyper.2006.09.003

  39. 39.

    Fung T.T., Chiuve S.E., McCullough M.L., Rexrode K.M., Logroscino G., Hu F.B. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch. Intern. Med. 2008;168:713-720.

    Not in our library10.1001/archinte.168.7.713

  40. 40.

    Levitan E.B., Wolk A., Mittleman M.A. Consistency with the DASH diet and incidence of heart failure. Arch. Intern. Med. 2009;169:851-857.

    Not in our library10.1001/archinternmed.2009.56

  41. 41.

    Lin P.H., Yeh W.T., Svetkey L.P., Chuang S.Y., Chang Y.C., Wang C., Pan W.H. Dietary intakes consistent with the DASH dietary pattern reduce blood pressure increase with age and risk for stroke in a Chinese population. Asia Pac. J. Clin. Nutr. 2013;22:482-491.

    Not in our library

  42. 42.

    Reedy J., Krebs-Smith S.M., Miller P.E., Liese A.D., Kahle L.L., Park Y., Subar A.F. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J. Nutr. 2014;144:881-889.

    Not in our library10.3945/jn.113.189407

  43. 43.

    Salehi-Abargouei A., Maghsoudi Z., Shirani F., Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases—incidence: A systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29:611-618.

    Not in our library10.1016/j.nut.2012.12.018

  44. 44.

    de Koning L., Chiuve S.E., Fung T.T., Willett W.C., Rimm E.B., Hu F.B. Diet-quality scores and the risk of type 2 diabetes in men. Diabetes Care. 2011;34:1150-1156.

    Not in our library10.2337/dc10-2352

  45. 45.

    Otto M.C., Padhye N.S., Bertoni A.G., Jacobs D.R., Mozaffarian D. Everything in Moderation—Dietary Diversity and Quality, Central Obesity and Risk of Diabetes. PLoS ONE. 2015;10:e0141341.

    Not in our library10.1371/journal.pone.0141341

  46. 46.

    Jacobs S., Harmon B.E., Boushey C.J., Morimoto Y., Wilkens L.R., Le Marchand L., Kroger J., Schulze M.B., Kolonel L.N., Maskarinec G. A priori-defined diet quality indexes and risk of type 2 diabetes: The Multiethnic Cohort. Diabetologia. 2015;58:98-112.

    Not in our library10.1007/s00125-014-3404-8

  47. 47.

    InterAct C. Adherence to predefined dietary patterns and incident type 2 diabetes in European populations: EPIC-InterAct Study. Diabetologia. 2014;57:321-333.

    Not in our library10.1007/s00125-013-3092-9

  48. 48.

    Liese A.D., Nichols M., Sun X., D’Agostino R.B., Haffner S.M. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes Care. 2009;32:1434-1436.

    Not in our library10.2337/dc09-0228

  49. 49.

    Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Vogt T.M., Cutler J.A., Windhauser M.M., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 1997;336:1117-1124.

    Not in our library10.1056/nejm199704173361601

  50. 50.

    Appel L.J., Champagne C.M., Harsha D.W., Cooper L.S., Obarzanek E., Elmer P.J., Stevens V.J., Vollmer W.M., Lin P.H., Svetkey L.P., et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093.

    Not in our library10.1001/jama.289.16.2083

  51. 51.

    Conlin P.R., Erlinger T.P., Bohannon A., Miller E.R., Appel L.J., Svetkey L.P., Moore T.J. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am. J. Hypertens. 2003;16:337-342.

    Not in our library10.1016/s0895-7061(03)00056-6

  52. 52.

    Lopes H.F., Martin K.L., Nashar K., Morrow J.D., Goodfriend T.L., Egan B.M. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension. 2003;41:422-430.

    Not in our library10.1161/01.hyp.0000053450.19998.11

  53. 53.

    Nowson C.A., Wattanapenpaiboon N., Pachett A. Low-sodium Dietary Approaches to Stop Hypertension-type diet including lean red meat lowers blood pressure in postmenopausal women. Nutr. Res. 2009;29:8-18.

    Not in our library10.1016/j.nutres.2008.12.002

  54. 54.

    Nowson C.A., Worsley A., Margerison C., Jorna M.K., Frame A.G., Torres S.J., Godfrey S.J. Blood pressure response to dietary modifications in free-living individuals. J. Nutr. 2004;134:2322-2329.

    Not in our library10.1093/jn/134.9.2322

  55. 55.

    Nowson C.A., Worsley A., Margerison C., Jorna M.K., Godfrey S.J., Booth A. Blood pressure change with weight loss is affected by diet type in men. Am. J. Clin. Nutr. 2005;81:983-989.

    Not in our library10.1093/ajcn/81.5.983

  56. 56.

    Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi T., Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28:2823-2831.

    Not in our library10.2337/diacare.28.12.2823

  57. 57.

    Azadbakht L., Surkan P.J., Esmaillzadeh A., Willett W.C. The Dietary Approaches to Stop Hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients. J. Nutr. 2011;141:1083-1088.

    Not in our library10.3945/jn.110.136739

  58. 58.

    Al-Solaiman Y., Jesri A., Mountford W.K., Lackland D.T., Zhao Y., Egan B.M. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. J. Hum. Hypertens. 2010;24:237-246.

    Not in our library10.1038/jhh.2009.58

  59. 59.

    Blumenthal J.A., Babyak M.A., Hinderliter A., Watkins L.L., Craighead L., Lin P.H., Caccia C., Johnson J., Waugh R., Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: The ENCORE study. Arch. Intern. Med. 2010;170:126-135.

    Not in our library10.1001/archinternmed.2009.470

  60. 60.

    Malloy-McFall J., Barkley J.E., Gordon K.L., Burzminski N., Glickman E.L. Effect of the DASH Diet on Pre- and Stage 1 Hypertensive Individuals in a Free-Living Environment. Nutr. Metab. Insights. 2010;3:15-23.

    Not in our library10.4137/nmi.s3871

  61. 61.

    Edwards K.M., Wilson K.L., Sadja J., Ziegler M.G., Mills P.J. Effects on blood pressure and autonomic nervous system function of a 12-week exercise or exercise plus DASH-diet intervention in individuals with elevated blood pressure. Acta Physiol. (Oxf.). 2011;203:343-350.

    Not in our library10.1111/j.1748-1716.2011.02329.x

  62. 62.

    Lin P.H., Allen J.D., Li Y.J., Yu M., Lien L.F., Svetkey L.P. Blood Pressure-Lowering Mechanisms of the DASH Dietary Pattern. J. Nutr. Metab. 2012;2012:472396.

    Not in our library10.1155/2012/472396

  63. 63.

    Asemi Z., Tabassi Z., Samimi M., Fahiminejad T., Esmaillzadeh A. Favourable effects of the Dietary Approaches to Stop Hypertension diet on glucose tolerance and lipid profiles in gestational diabetes: A randomised clinical trial. Br. J. Nutr. 2013;109:2024-2030.

    Not in our library10.1017/s0007114512004242

  64. 64.

    Shirani F., Salehi-Abargouei A., Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: A systematic review and meta-analysis on controlled clinical trials. Nutrition. 2013;29:939-947.

    Not in our library10.1016/j.nut.2012.12.021

  65. 65.

    Soltani S., Shirani F., Chitsazi M.J., Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: A systematic review and meta-analysis of randomized controlled clinical trials. Obes. Rev. 2016;17:442-454.

    Not in our library10.1111/obr.12391

  66. 66.

    Soltani S., Chitsazi M.J., Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) on serum inflammatory markers: A systematic review and meta-analysis of randomized trials. Clin. Nutr. 2018;37:542-550.

    Not in our library10.1016/j.clnu.2017.02.018

  67. 67.

    Harsha D.W., Sacks F.M., Obarzanek E., Svetkey L.P., Lin P.H., Bray G.A., Aickin M., Conlin P.R., Miller E.R., Appel L.J. Effect of dietary sodium intake on blood lipids: Results from the DASH-sodium trial. Hypertension. 2004;43:393-398.

    Not in our library10.1161/01.hyp.0000113046.83819.a2

  68. 68.

    Chen S.T., Maruthur N.M., Appel L.J. The effect of dietary patterns on estimated coronary heart disease risk: Results from the Dietary Approaches to Stop Hypertension (DASH) trial. Circ. Cardiovasc. Qual. Outcomes. 2010;3:484-489.

    Not in our library10.1161/circoutcomes.109.930685

  69. 69.

    Ard J.D., Grambow S.C., Liu D., Slentz C.A., Kraus W.E., Svetkey L.P., study P. The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care. 2004;27:340-347.

    Not in our library10.2337/diacare.27.2.340

  70. 70.

    Lien L.F., Brown A.J., Ard J.D., Loria C., Erlinger T.P., Feldstein A.C., Lin P.H., Champagne C.M., King A.C., McGuire H.L., et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50:609-616.

    Not in our library10.1161/hypertensionaha.107.089458

  71. 71.

    Al-Solaiman Y., Jesri A., Zhao Y., Morrow J.D., Egan B.M. Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J. Hum. Hypertens. 2009;23:826-835.

    Not in our library10.1038/jhh.2009.32

  72. 72.

    Hodson L., Harnden K.E., Roberts R., Dennis A.L., Frayn K.N. Does the DASH diet lower blood pressure by altering peripheral vascular function? J. Hum. Hypertens. 2010;24:312-319.

    Not in our library10.1038/jhh.2009.65

  73. 73.

    Ard J.D., Coffman C.J., Lin P.H., Svetkey L.P. One-year follow-up study of blood pressure and dietary patterns in dietary approaches to stop hypertension (DASH)-sodium participants. Am. J. Hypertens. 2004;17:1156-1162.

    Not in our library10.1016/j.amjhyper.2004.07.005

  74. 74.

    Elmer P.J., Obarzanek E., Vollmer W.M., Simons-Morton D., Stevens V.J., Young D.R., Lin P.H., Champagne C., Harsha D.W., Svetkey L.P., et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann. Intern. Med. 2006;144:485-495.

    Not in our library10.7326/0003-4819-144-7-200604040-00007

  75. 75.

    Lima S.T., da Silva Nalin de Souza B., Franca A.K., Salgado Filho N., Sichieri R. Dietary approach to hypertension based on low glycaemic index and principles of DASH (Dietary Approaches to Stop Hypertension): A randomised trial in a primary care service. Br. J. Nutr. 2013;110:1472-1479.

    Not in our library10.1017/s0007114513000718

  76. 76.

    Rifai L., Pisano C., Hayden J., Sulo S., Silver M.A. Impact of the DASH diet on endothelial function, exercise capacity, and quality of life in patients with heart failure. Bayl. Univ. Med. Cent. Proc. 2015;28:151-156.

    Not in our library10.1080/08998280.2015.11929216

  77. 77.

    Asemi Z., Samimi M., Tabassi Z., Esmaillzadeh A. The effect of DASH diet on pregnancy outcomes in gestational diabetes: A randomized controlled clinical trial. Eur. J. Clin. Nutr. 2014;68:490-495.

    Not in our library10.1038/ejcn.2013.296

  78. 78.

    Razavi Zade M., Telkabadi M.H., Bahmani F., Salehi B., Farshbaf S., Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: A randomized clinical trial. Liver Int. 2016;36:563-571.

    Not in our library10.1111/liv.12990

  79. 79.

    Jenkins D.J., Jones P.J., Frohlich J., Lamarche B., Ireland C., Nishi S.K., Srichaikul K., Galange P., Pellini C., Faulkner D., et al. The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. Nutr. Metab. Cardiovasc. Dis. 2015;25:1132-1139.

    Not in our library10.1016/j.numecd.2015.08.006

  80. 80.

    King D.E., Egan B.M., Woolson R.F., Mainous A.G., Al-Solaiman Y., Jesri A. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch. Intern. Med. 2007;167:502-506.

    Not in our library10.1001/archinte.167.5.502

  81. 81.

    Roussell M.A., Hill A.M., Gaugler T.L., West S.G., Heuvel J.P., Alaupovic P., Gillies P.J., Kris-Etherton P.M. Beef in an Optimal Lean Diet study: Effects on lipids, lipoproteins, and apolipoproteins. Am. J. Clin. Nutr. 2012;95:9-16.

    Not in our library10.3945/ajcn.111.016261

  82. 82.

    Wang X., Ouyang Y., Liu J., Zhu M., Zhao G., Bao W., Hu F.B. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: Systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490.

    Not in our library10.1136/bmj.g4490

  83. 83.

    Tang G., Wang D., Long J., Yang F., Si L. Meta-analysis of the association between whole grain intake and coronary heart disease risk. Am. J. Cardiol. 2015;115:625-629.

    Not in our library10.1016/j.amjcard.2014.12.015

  84. 84.

    Reynolds A.N. Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? Lancet. 2018;391:1676.

    Not in our library10.1016/s0140-6736(18)30845-6

  85. 85.

    Viguiliouk E., Blanco Mejia S., Kendall C.W., Sievenpiper J.L. Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta-analyses. Ann. N. Y. Acad. Sci. 2017;1392:43-57.

    Not in our library10.1111/nyas.13312

  86. 86.
    Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies · 2016
    No notice
  87. 87.

    Abete I., Romaguera D., Vieira A.R., Lopez de Munain A., Norat T. Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: A meta-analysis of cohort studies. Br. J. Nutr. 2014;112:762-775.

    Not in our library10.1017/s000711451400124x

  88. 88.

    Wang X., Lin X., Ouyang Y.Y., Liu J., Zhao G., Pan A., Hu F.B. Red and processed meat consumption and mortality: Dose-response meta-analysis of prospective cohort studies. Public Health Nutr. 2016;19:893-905.

    Not in our library10.1017/s1368980015002062

  89. 89.

    Threapleton D.E., Greenwood D.C., Evans C.E., Cleghorn C.L., Nykjaer C., Woodhead C., Cade J.E., Gale C.P., Burley V.J. Dietary fibre intake and risk of cardiovascular disease: Systematic review and meta-analysis. BMJ. 2013;347:f6879.

    Not in our library10.1136/bmj.f6879

  90. 90.

    Arts I.C., Hollman P.C. Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr. 2005;81:317S-325S.

    Not in our library10.1093/ajcn/81.1.317s

  91. 91.

    Perez-Cano F.J., Castell M. Flavonoids, Inflammation and Immune System. Nutrients. 2016;8:659.

    Not in our library10.3390/nu8100659

  92. 92.

    Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., Amann M., Anderson H.R., Andrews K.G., Aryee M., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260.

    Not in our library10.1016/s0140-6736(12)61766-8

  93. 93.

    Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Prospective Studies, Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.

    Not in our library10.1016/s0140-6736(02)11911-8

  94. 94.

    Cholesterol Treatment Trialists Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.

    Not in our library10.1016/s0140-6736(10)61350-5

  95. 95.

    Cholesterol Treatment Trialists Collaboration, Fulcher J., O’Connell R., Voysey M., Emberson J., Blackwell L., Mihaylova B., Simes J., Collins R., Kirby A., et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-1405.

    Not in our library10.1016/s0140-6736(14)61368-4

  96. 96.

    Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015;372:2387-2397.

    Not in our library10.1056/nejmoa1410489

  97. 97.

    Johnston B.C., Kanters S., Bandayrel K., Wu P., Naji F., Siemieniuk R.A., Ball G.D., Busse J.W., Thorlund K., Guyatt G., et al. Comparison of weight loss among named diet programs in overweight and obese adults: A meta-analysis. JAMA. 2014;312:923-933.

    Not in our library10.1001/jama.2014.10397

  98. 98.

    Haslam D.W., James W.P. Obesity. Lancet. 2005;366:1197-1209.

    Not in our library10.1016/s0140-6736(05)67483-1

  99. 99.

    Sotos-Prieto M., Bhupathiraju S.N., Mattei J., Fung T.T., Li Y., Pan A., Willett W.C., Rimm E.B., Hu F.B. Association of Changes in Diet Quality with Total and Cause-Specific Mortality. N. Engl. J. Med. 2017;377:143-153.

    Not in our library10.1056/nejmoa1613502

  100. 100.

    Li M., Fan Y., Zhang X., Hou W., Tang Z. Fruit and vegetable intake and risk of type 2 diabetes mellitus: Meta-analysis of prospective cohort studies. BMJ Open. 2014;4:e005497.

    Not in our library10.1136/bmjopen-2014-005497

  101. 101.

    Gijsbers L., Ding E.L., Malik V.S., de Goede J., Geleijnse J.M., Soedamah-Muthu S.S. Consumption of dairy foods and diabetes incidence: A dose-response meta-analysis of observational studies. Am. J. Clin. Nutr. 2016;103:1111-1124.

    Not in our library10.3945/ajcn.115.123216

  102. 102.

    Wei G.S., Coady S.A., Goff D.C., Brancati F.L., Levy D., Selvin E., Vasan R.S., Fox C.S. Blood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care. 2011;34:873-879.

    Not in our library10.2337/dc10-1786

  103. 103.
    Usual Blood Pressure and Risk of New-Onset Diabetes · 2015
    No notice
  104. 104.

    Marott S.C., Nordestgaard B.G., Tybjaerg-Hansen A., Benn M. Components of the Metabolic Syndrome and Risk of Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2016;101:3212-3221.

    Not in our library10.1210/jc.2015-3777

  105. 105.

    Post R.E., Mainous A.G., King D.E., Simpson K.N. Dietary fiber for the treatment of type 2 diabetes mellitus: A meta-analysis. J. Am. Board Fam. Med. 2012;25:16-23.

    Not in our library10.3122/jabfm.2012.01.110148

  106. 106.

    Evans C.E., Greenwood D.C., Threapleton D.E., Cleghorn C.L., Nykjaer C., Woodhead C.E., Gale C.P., Burley V.J. Effects of dietary fibre type on blood pressure: A systematic review and meta-analysis of randomized controlled trials of healthy individuals. J. Hypertens. 2015;33:897-911.

    Not in our library10.1097/hjh.0000000000000515

  107. 107.

    Hou Q., Li Y., Li L., Cheng G., Sun X., Li S., Tian H. The Metabolic Effects of Oats Intake in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients. 2015;7:10369-10387.

    Not in our library10.3390/nu7125536

  108. 108.

    Sievenpiper J.L., Kendall C.W., Esfahani A., Wong J.M., Carleton A.J., Jiang H.Y., Bazinet R.P., Vidgen E., Jenkins D.J. Effect of non-oil-seed pulses on glycaemic control: A systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia. 2009;52:1479-1495.

    Not in our library10.1007/s00125-009-1395-7

  109. 109.

    Choo V.L., Viguiliouk E., Blanco Mejia S., Cozma A.I., Khan T.A., Ha V., Wolever T.M.S., Leiter L.A., Vuksan V., Kendall C.W.C., et al. Food sources of fructose-containing sugars and glycaemic control: Systematic review and meta-analysis of controlled intervention studies. BMJ. 2018;363:k4644.

    Not in our library10.1136/bmj.k4644

  110. 110.
    Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies · 2015
    No notice
  111. 111.

    Aune D., Norat T., Romundstad P., Vatten L.J. Whole grain and refined grain consumption and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. Eur. J. Epidemiol. 2013;28:845-858.

    Not in our library10.1007/s10654-013-9852-5

  112. 112.

    Kotchen T.A., Kotchen J.M. Dietary sodium and blood pressure: Interactions with other nutrients. Am. J. Clin. Nutr. 1997;65:708S-711S.

    Not in our library10.1093/ajcn/65.2.708s

  113. 113.

    Whelton P.K., He J., Cutler J.A., Brancati F.L., Appel L.J., Follmann D., Klag M.J. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 1997;277:1624-1632.

    Not in our library10.1001/jama.1997.03540440058033

  114. 114.

    Petrov V., Lijnen P. Modification of intracellular calcium and plasma renin by dietary calcium in men. Am. J. Hypertens. 1999;12:1217-1224.

    Not in our library10.1016/s0895-7061(99)00126-0

  115. 115.

    Kanbay M., Bayram Y., Solak Y., Sanders P.W. Dietary potassium: A key mediator of the cardiovascular response to dietary sodium chloride. J. Am. Soc. Hypertens. 2013;7:395-400.

    Not in our library10.1016/j.jash.2013.04.009

  116. 116.

    Haddy F.J., Vanhoutte P.M., Feletou M. Role of potassium in regulating blood flow and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006;290:R546-R552.

    Not in our library10.1152/ajpregu.00491.2005

  117. 117.

    Zacchia M., Abategiovanni M.L., Stratigis S., Capasso G. Potassium: From Physiology to Clinical Implications. Kidney Dis. (Basel). 2016;2:72-79.

    Not in our library10.1159/000446268

  118. 118.

    Siervo M., Lara J., Ogbonmwan I., Mathers J.C. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: A systematic review and meta-analysis. J. Nutr. 2013;143:818-826.

    Not in our library10.3945/jn.112.170233

  119. 119.

    Jayalath V.H., de Souza R.J., Sievenpiper J.L., Ha V., Chiavaroli L., Mirrahimi A., Di Buono M., Bernstein A.M., Leiter L.A., Kris-Etherton P.M., et al. Effect of dietary pulses on blood pressure: A systematic review and meta-analysis of controlled feeding trials. Am. J. Hypertens. 2014;27:56-64.

    Not in our library10.1093/ajh/hpt155

  120. 120.

    Huang H., Chen G., Liao D., Zhu Y., Xue X. Effects of Berries Consumption on Cardiovascular Risk Factors: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled Trials. Sci. Rep. 2016;6:23625.

    Not in our library10.1038/srep23625

  121. 121.

    Khan K., Jovanovski E., Ho H.V.T., Marques A.C.R., Zurbau A., Mejia S.B., Sievenpiper J.L., Vuksan V. The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2018;28:3-13.

    Not in our library10.1016/j.numecd.2017.09.007

  122. 122.

    Ho H.V., Sievenpiper J.L., Zurbau A., Blanco Mejia S., Jovanovski E., Au-Yeung F., Jenkins A.L., Vuksan V. The effect of oat beta-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: A systematic review and meta-analysis of randomised-controlled trials. Br. J. Nutr. 2016;116:1369-1382.

    Not in our library10.1017/s000711451600341x

  123. 123.

    Hollaender P.L., Ross A.B., Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: A systematic review and meta-analysis of randomized controlled studies. Am. J. Clin. Nutr. 2015;102:556-572.

    Not in our library10.3945/ajcn.115.109165

  124. 124.

    Ha V., Sievenpiper J.L., de Souza R.J., Jayalath V.H., Mirrahimi A., Agarwal A., Chiavaroli L., Mejia S.B., Sacks F.M., Di Buono M., et al. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: A systematic review and meta-analysis of randomized controlled trials. CMAJ. 2014;186:E252-E262.

    Not in our library10.1503/cmaj.131727

  125. 125.

    Hooper L., Martin N., Abdelhamid A., Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst. Rev. 2015.

    Not in our library10.1002/14651858.cd011737

  126. 126.

    Chiavaroli L., Nishi S.K., Khan T.A., Braunstein C.R., Glenn A.J., Mejia S.B., Rahelic D., Kahleova H., Salas-Salvado J., Jenkins D.J.A., et al. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. Prog. Cardiovasc. Dis. 2018;61:43-53.

    Not in our library10.1016/j.pcad.2018.05.004

  127. 127.
    Systematic review and meta-analysis of the effect of increased vegetable and fruit consumption on body weight and energy intake · 2014
    Corrected
  128. 128.

    Howarth N.C., Saltzman E., Roberts S.B. Dietary fiber and weight regulation. Nutr. Rev. 2001;59:129-139.

    Not in our library10.1111/j.1753-4887.2001.tb07001.x

  129. 129.

    Kim S.J., de Souza R.J., Choo V.L., Ha V., Cozma A.I., Chiavaroli L., Mirrahimi A., Blanco Mejia S., Di Buono M., Bernstein A.M., et al. Effects of dietary pulse consumption on body weight: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2016;103:1213-1223.

    Not in our library10.3945/ajcn.115.124677

  130. 130.

    Li S.S., Kendall C.W., de Souza R.J., Jayalath V.H., Cozma A.I., Ha V., Mirrahimi A., Chiavaroli L., Augustin L.S., Blanco Mejia S., et al. Dietary pulses, satiety and food intake: A systematic review and meta-analysis of acute feeding trials. Obesity (Silver Spring). 2014;22:1773-1780.

    Not in our library10.1002/oby.20782

  131. 131.

    Oh S.W., Han K.H., Han S.Y., Koo H.S., Kim S., Chin H.J. Association of Sodium Excretion With Metabolic Syndrome, Insulin Resistance, and Body Fat. Medicine (Baltimore). 2015;94:e1650.

    Not in our library10.1097/md.0000000000001650

  132. 132.

    Jiao J., Xu J.Y., Zhang W., Han S., Qin L.Q. Effect of dietary fiber on circulating C-reactive protein in overweight and obese adults: A meta-analysis of randomized controlled trials. Int. J. Food Sci. Nutr. 2015;66:114-119.

    Not in our library10.3109/09637486.2014.959898

  133. 133.

    Estruch R., Martinez-Gonzalez M.A., Corella D., Basora-Gallisa J., Ruiz-Gutierrez V., Covas M.I., Fiol M., Gomez-Gracia E., Lopez-Sabater M.C., Escoda R., et al. Effects of dietary fibre intake on risk factors for cardiovascular disease in subjects at high risk. J. Epidemiol. Community Health. 2009;63:582-588.

    Not in our library10.1136/jech.2008.082214

  134. 134.

    Kanauchi O., Mitsuyama K., Araki Y., Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr. Pharm Des. 2003;9:333-346.

    Not in our library10.2174/1381612033391883

  135. 135.

    Scheppach W., Wiggins H.S., Halliday D., Self R., Howard J., Branch W.J., Schrezenmeir J., Cummings J.H. Effect of gut-derived acetate on glucose turnover in man. Clin. Sci. (Lond.). 1988;75:363-370.

    Not in our library10.1042/cs0750363

  136. 136.

    Lee Y., Kang D., Lee S.A. Effect of dietary patterns on serum C-reactive protein level. Nutr. Metab. Cardiovasc. Dis. 2014;24:1004-1011.

    Not in our library10.1016/j.numecd.2014.05.001

  137. 137.

    Watzl B., Kulling S.E., Moseneder J., Barth S.W., Bub A. A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. Am. J. Clin. Nutr. 2005;82:1052-1058.

    Not in our library10.1093/ajcn/82.5.1052

  138. 138.

    Dibaba D.T., Xun P., He K. Dietary magnesium intake is inversely associated with serum C-reactive protein levels: Meta-analysis and systematic review. Eur. J. Clin. Nutr. 2014;68:971.

    Not in our library10.1038/ejcn.2014.111

  139. 139.

    Almoznino-Sarafian D., Berman S., Mor A., Shteinshnaider M., Gorelik O., Tzur I., Alon I., Modai D., Cohen N. Magnesium and C-reactive protein in heart failure: An anti-inflammatory effect of magnesium administration? Eur. J. Nutr. 2007;46:230-237.

    Not in our library10.1007/s00394-007-0655-x

  140. 140.

    Chen X., Touyz R.M., Park J.B., Schiffrin E.L. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38:606-611.

    Not in our library10.1161/hy09t1.094005

  141. 141.

    Yang Y., Gao M., Nie W., Yuan J., Zhang B., Wang Z., Wu Z. Dietary magnesium sulfate supplementation protects heat stress-induced oxidative damage by restoring the activities of anti-oxidative enzymes in broilers. Biol. Trace Elem. Res. 2012;146:53-58.

    Not in our library10.1007/s12011-011-9210-y

  142. 142.

    Blanco Mejia S., Kendall C.W., Viguiliouk E., Augustin L.S., Ha V., Cozma A.I., Mirrahimi A., Maroleanu A., Chiavaroli L., Leiter L.A., et al. Effect of tree nuts on metabolic syndrome criteria: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2014;4:e004660.

    Not in our library10.1136/bmjopen-2013-004660

  143. 143.

    Ho H.V., Sievenpiper J.L., Zurbau A., Blanco Mejia S., Jovanovski E., Au-Yeung F., Jenkins A.L., Vuksan V. A systematic review and meta-analysis of randomized controlled trials of the effect of barley beta-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction(i-iv). Eur. J. Clin. Nutr. 2016;70:1340.

    Not in our library10.1038/ejcn.2016.129

  144. 144.

    Health Promotion and Disease Prevention: Fruit and Vegetables. European Commission.

    Not in our library

  145. 145.

    Health Promotion and Disease Prevention: Dietary Fats. European Commission.

    Not in our library

  146. 146.

    Hjartaker A., Lagiou A., Slimani N., Lund E., Chirlaque M.D., Vasilopoulou E., Zavitsanos X., Berrino F., Sacerdote C., Ocke M.C., et al. Consumption of dairy products in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: Data from 35,955 24-hour dietary recalls in 10 European countries. Public Health Nutr. 2002;5:1259-1271.

    Not in our library10.1079/phn2002403

  147. 147.
    Disparities in State-Specific Adult Fruit and Vegetable Consumption — United States, 2015 · 2017
    No notice
  148. 148.

    U. S. Department of Agricultural Service. Food Patterns Equivalents Intakes from Food: Mean Amounts Consumed per Individual, by Gender and Age, What We Eat In America, NHANES 2009–2010. 2013.

    Not in our library

  149. 149.

    Nielsen S.J., Kit B.K., Ogden C.L. Nut Consumption Among U.S. Adults, 2009–2010. NCHS Data Brief. 2014;176:1-8.

    Not in our library

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.